Article Text

Download PDFPDF
Drug-eluting balloon for instent restenosis
  1. Rahul Bahl1,
  2. Andreas Indermuehle2,
  3. Georg M Froehlich1,
  4. Alexandra J Lansky3,
  5. Guido Knapp4,
  6. Adam Timmis5,
  7. Pascal Meier1,3
  1. 1 Department of Cardiology, University College London Hospitals, London, UK
  2. 2 Department of Cardiology, Hospital Biel, Biel, Switzerland
  3. 3 Division of Cardiology, Yale Medical School, New Haven, Connecticut, USA
  4. 4 Department of Statistics, TU University of Dortmund, Dortmund, Germany
  5. 5 NIHR Biomedical Research Unit, Barts and the London School of Medicine and Dentistry, London Chest Hospital, London, UK
  1. Correspondence to Dr Pascal Meier, Division of Cardiology, Yale Medical School, New Haven, CT, USA CT06510; Department of Cardiology, University College London UCL Hospitals, London W1G 8PH, UK; pascalmeier74{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The Authors’ reply We thank Chen et al 1 for their feedback on our paper2 and we fully agree with most of their comments. Instent restenosis continues to be a problem even though the risk has been massively reduced by drug coating of stents.3 A significant proportion of patients had contraindications for drug-eluting stents (DES).

Regarding the short-term and long-term follow-up data available for the PACCOCATH trial, we generally …

View Full Text


  • Contributors RB: drafted the first draft of the reply letter. AI, GMF, AJL, GK, AT and PM: critical revision for its intellectual content.

  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles